AAV递送shRNA抑制mTOR在大鼠OIR模型中的抗血管生成基因治疗研究
本研究在大鼠氧诱导视网膜病变(OIR)模型中,通过玻璃体腔注射表达shRNA的重组腺相关病毒(rAAV2-shmTOR-GFP)抑制mTOR,评估其抗病理性视网膜血管生成的效果。结果显示rAAV2-shmTOR-GFP显著减少新生血管面积百分比(4.28 ± 2.86 vs 对照20.95 ± 6.85,P = 0.00103),并减少无血管区和血管迂曲度,同时减少炎症细胞浸润和具有抗凋亡作用。结论提示rAAV2-shmTOR-GFP有望成为治疗新生血管性视网膜疾病的有效便捷基因疗法。
要点
- rAAV2-shmTOR-GFP玻璃体腔注射显著减少OIR大鼠视网膜新生血管面积百分比。
- 该治疗同时改善视网膜无血管区和血管迂曲度,效果优于对照。
- 病毒载体减少视网膜炎症细胞浸润并具有抗凋亡特性。
核心结论
- rAAV2-shmTOR-GFP作为有效便捷的基因疗法,对治疗新生血管性视网膜疾病有较强前景。
研究设计与样本
- 使用Sprague-Dawley幼鼠建立氧诱导视网膜病变(OIR)模型,在返回常氧时玻璃体腔注射rAAV2-shmTOR-GFP并设对照。
主要发现
- 与正常对照、未治疗OIR(20.95 ± 6.85)、模拟治疗(14.50 ± 2.47)和对照shRNA病毒载体(16.64 ± 4.92)相比,rAAV2-shmTOR-GFP组新生血管面积百分比显著降低(4.28 ± 2.86,P = 0.00103)。
- 视网膜无血管区和血管迂曲度的定量结果与新生血管面积结果一致,rAAV2-shmTOR-GFP疗效显著优于其他处理。
- 病毒载体减少炎症细胞浸润入视网膜组织,并具有抗凋亡特性。
关键数值与推荐
- OIR模型未治疗组新生血管面积百分比为20.95 ± 6.85,rAAV2-shmTOR-GFP组为4.28 ± 2.86,P = 0.00103。
- 模拟治疗组新生血管面积百分比为14.50 ± 2.47,对照shRNA病毒载体组为16.64 ± 4.92。
临床怎么用
- 抑制mTOR的基因治疗策略可能用于新生血管性视网膜疾病,但尚需临床前进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Recent studies have shown that inhibitors of the mechanistic target of rapamycin (mTOR) play important roles in proliferating endothelial cells within the retinal vasculature. Here we explore the effects of inhibiting mTOR as a potential gene therapeutic against pathological retinal angiogenesis in a rat model of oxygen-induced retinopathy (OIR). METHODS: Sprague-Dawley pups were used to generate the OIR model, with a recombinant adeno-associated virus expressing an shRNA (rAAV2-shmTOR-GFP) being administered via intravitreal injection on returning the rats to normoxia, with appropriate controls. Immunohistochemistry and TUNEL assays, as well as fluorescein angiography, were performed on transverse retinal sections and flat mounts, respectively, to determine the in vivo effects of mTOR inhibition. RESULTS: Compared with normal control rats, as well as OIR model animals that were either untreated (20.95 ± 6.85), mock-treated (14.50 ± 2.47), or injected with a control short hairpin RNA (shRNA)-containing virus vector (16.64 ± 4.92), rAAV2-shmTOR-GFP (4.28 ± 2.86, P = 0.00103) treatment resulted in dramatically reduced neovascularization as a percentage of total retinal area. These results mirrored quantifications of retinal avascular area and vessel tortuosity, with rAAV2-shmTOR-GFP exhibiting significantly greater therapeutic efficacy than the other treatments. The virus vector was additionally shown to reduce inflammatory cell infiltration into retinal tissue and possess antiapoptotic properties, both these processes having been implicated in the pathophysiology of angiogenic retinal disorders. CONCLUSIONS: Taken together, these results demonstrate the strong promise of rAAV2-shmTOR-GFP as an effective and convenient gene therapy for the treatment of neovascular retinal diseases.
引用
- Lee SHS, Chang H, Kim JH, et al. Inhibition of mTOR via an AAV-Delivered shRNA Tested in a Rat OIR Model as a Potential Antiangiogenic Gene Therapy. Invest Ophthalmol Vis Sci. 2020. PMID: 32106292. doi:10.1167/iovs.61.2.45
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。